Jenny Harrington, CEO, Gilman Hill Asset ManagementClorox CompanyCLXBUYMar 25, 2026
She bought it because it trades at 16x vs. historically 18-20x, and pays a safe 4.9% dividend which has increased for 24 years in company history. Rocked by Covid, only now are earnings are finding a consistent trajectory of 6-8% earnings growth with dividend growth. From Jan.1 to Feb. 9, shares jumped 26%, but shares fell when the Iran war began, because many of their products rely on oil. Whenever the oil price goes down, these shares go up. Also, it's AI proof.
It reports Monday. It's down over 30% this year. It's at the heart of this market's conundrum. When there were worries over the economy, everybody bought the consumer packaged goods stocks. Now, perhaps because of inflation, people won't pay up for the name brands. See what the CEO has to say.
Still really expensive at over 30x earnings for a consumer product. Not fantastic growth. Relatively weak balance sheet, lots of debt. Fairly well managed. Cost-cutting efforts can only go so far. Be careful.
Nvidia is trading at the same forward PE as Clorox. It's worth looking at these quality growth names with real earnings and cash flows, because inflation will peak and the market will re-rate what the Fed will do. Investors will position themselves in such names in the second half of this year.
They reported a mixed quarter on Monday. Rampant cost inflation is eating alive consumer product companies which should be thriving at this stage of the cycle. Clorox has been an awful performer and many have been shorting this. They reported declining gross margins and they shaved 20 cents off their full-year earnings forecast, but they were better than expected in the previous quarter. CLorox reported a 39-cent earnings beat and announced another round of price increases for July which should help margin compression. The stock has recovered from Monday's losses and then some. The company has room to run, especially if the Fed can kill inflation.
They report Monday. They've had some awful quarters, so they only need to report a decent quarter to push prices rise. They need to do something with their supplements business, which is lousy.
(A Top Pick Mar 08/21, Down 26%) Doesn't own stock anymore even though has recommended it to investors.
Simple and straight forward product that everyone uses.
Could not justify investment.
(A Top Pick Feb 09/21, Down 12.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CLX has triggered its stop at $165. To remain disciplined, we recommend covering the position at this time.
(A Top Pick Feb 09/21, Down 2.9%)Stockchase Research Editor: Michael O'Reilly To ensure progressing capital returns of our PAST TOP PICK with CLX, we recommend trailing the stop (from $150) to $165.
A big winner last year for obvious reasons, nut it's been selling off the past 9 months as the reopening approaches and as the company faces tough comps. Today, they delivered a mixed quarter of a topline miss and bottom line beat, and management adjusted down their full-year earnings forecast. It's $5 from its 52-week low. Has this fully de-risked? Does it face rising costs?
She bought it because it trades at 16x vs. historically 18-20x, and pays a safe 4.9% dividend which has increased for 24 years in company history. Rocked by Covid, only now are earnings are finding a consistent trajectory of 6-8% earnings growth with dividend growth. From Jan.1 to Feb. 9, shares jumped 26%, but shares fell when the Iran war began, because many of their products rely on oil. Whenever the oil price goes down, these shares go up. Also, it's AI proof.